INCY: Summary for Incyte Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 1:47am EST - Canadian Markets open in 7 hours and 43 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Incyte Corporation (INCY)

On Feb 9: 10.28 USD

0.32 (3.21%)

MORE ON INCY

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Incyte Corporation (NGM:INCY) Delayed quote data

After Hours: 9.96

0.32 (3.11%) as of 5:00pm EST on 02/09/10

Last Trade:	10.28 USD
Trade Time:	Feb 9
Change:	0.32 (3.21%)
Prev Close:	9.96
Open:	10.23
Bid:	9.98 x 500
Ask:	N/A
1y Target Est:	14.33

Day's Range:	10.07 - 10.45
52wk Range:	1.96 - 11.24
Volume:	2,102,388
Avg Vol (3m):	3,302,710
Market Cap:	1.22B
P/E (ttm):	N/A
EPS (ttm):	-1.02
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add INCY to Portfolio

Download Data

HEADLINES

•	Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
	Business Wire (Tue 4:16pm)

•	Nektar adds to board of directors
	at bizjournals.com (Tue, Feb 2)

•	Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due 2011 and Its 3½% Convertible Subordinated Notes Due 2011
	Business Wire (Thu, Jan 28)

•	Eli Lilly Misses by a Penny
	Zacks.com (Thu, Jan 28)

•	Another Deal for Novartis
	Zacks.com (Wed, Jan 20)

•	Incyte to Present at the 28th Annual JPMorgan Healthcare Conference
	Business Wire (Tue, Jan 5)

•	Analysts Name Top Biotech Stocks for 2010: BioBuzz
	at TheStreet.com (Tue, Jan 5)

•	Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
	at Seeking Alpha (Thu, Dec 24)

•	Pharma Spreads Holiday Cheer in Bevy of Biotech Deals
	at Seeking Alpha (Thu, Dec 24)

•	Lightning Round OT: Kinder Morgan Energy, Incyte and More
	at CNBC (Wed, Dec 23)

•	Another Deal for Incyte
	Zacks.com (Tue, Dec 22)

•	Some Incyte Into Why These Drugs Rock
	at Motley Fool (Tue, Dec 22)

•	Deal activity lifts US stocks
	at FT.com (Mon, Dec 21)

•	INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
	EDGAR Online (Mon, Dec 21)

•	Pharma's Holiday Shopping Spree
	at CNBC (Mon, Dec 21)

•	Incyte shares rise on Eli Lilly deal
	AP (Mon, Dec 21)

•	A Slew of New Deals Move Pharma Stocks
	Indie Research (Mon, Dec 21)

More Headlines for INCY...

ANALYST

EPS Est (next year) (Dec-07) :	-1.06
EPS Est (in 2 years) (Dec-08) :	-1.39
Avg Rec (current)*:	2.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Incyte Corporation is a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•